Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR)
Industry: Healthcare

Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection. Its product candidates that are in Phase II clinical trial include Lambda, which targets type III IFN receptors; Exendin 9-39 for treating post-bariatric hypoglycemia; and Ubenimex, an oral, small-molecule inhibitor of leukotriene A4 hydrolase for treating lymphedema. The company was founded in 2008 and is headquartered in Palo Alto, California.

Current Quote*
Last: $10.150
Change: -0.070
Book: $2.815
Volume: 22,031

As Of: 10/15 16:34 ET
*Quotes delayed by 20min.

Graphs for EIGR


3 Month Graph


6 Month Graph


1 Year Graph